Siamab Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies. Siamab has developed a platform of technologies that enable the rapid discovery and development of therapeutic antibodies that bind to a novel class of carbohydrate antigens present on cancer cells. The company’s lead program is in preclinical studies for the treatment of solid tumors.
October 8, 2014
Siamab Therapeutics Appoints Robert Mashal to Board of Directors; Receives SBIR grant focused on cancer stem cells; Research to be conducted in collaboration with Massachusetts General Hospital